Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study
| العنوان: | Efficacy and safety of autologous bone marrow derived hematopoietic stem cell transplantation in patients with type 2 DM: A 15 months follow-up study |
|---|---|
| المؤلفون: | R. R. Sharma, Vivek Gupta, Shobhit Bhansali, Sandeep Grover, Anil Bhansali, Vimal Upreti, Neelam Marwaha, Niranjan Khandelwal, Rama Walia |
| المصدر: | Indian Journal of Endocrinology and Metabolism Indian Journal of Endocrinology and Metabolism, Vol 18, Iss 6, Pp 838-845 (2014) |
| بيانات النشر: | Medknow Publications & Media Pvt Ltd, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, β-cells, Hematopoietic stem cell transplantation, Type 2 diabetes, Gastroenterology, lcsh:Diseases of the endocrine glands. Clinical endocrinology, chemistry.chemical_compound, Endocrinology, Quality of life, stem cells, Internal medicine, Medicine, lcsh:RC799-869, Adverse effect, lcsh:RC648-665, business.industry, C-peptide, Insulin, medicine.disease, Surgery, Metformin, chemistry, lcsh:Diseases of the digestive system. Gastroenterology, Original Article, business, Pioglitazone, medicine.drug |
| الوصف: | Background: there are dearths of studies describing the effect of autologous bone marrow derived stem cell transplantation (ABMSCT) through targeted approach in Type 2 Diabetes Mellitus. This study reports the efficacy and safety of super-selective injection of ABMSCT in T2DM. Materials and Methods: Ten patients (8 men and 2 women) with T2DM, with duration of disease >5 years and with documented triple drug failure receiving insulin (0.7 U/Kg/day), metformin and pioglitazone underwent super-selective injection of stem cells into superior pancreaticoduodenal artery under fluoroscopic guidance. The primary outcome measure was decrease in insulin requirement by ≥50% (defined as responders), while secondary endpoints were improvement in glucagon stimulated C-peptide levels, changes in weight, HbA1c, lipid profile and quality of life (QOL) at the end of 15 months. Results: Six patients (60%) were ‘responders’ at 15 months of follow-up showing a reduction in mean insulin requirement by 74% as compared to baseline and one patient was off-insulin till the end of the study. Mean HbA1c reduction in ‘responders’ was 1.1% (8.1 ± 0.5% to 7.0 ± 0.6%, P = 0.03), accompanied with a significant improvement in glucagon stimulated C-peptide levels (P = 0.03), Homeostasis Model Assessment -β (P = 0.03) and QOL scores. However, ‘non-responders’ did not show any significant alterations in these parameters. No serious adverse events were noted. Conclusion: Our observations indicate that ABMSCT is effective in management of T2DM and its efficacy is maintained over a period of 15 months without any adverse events. However, more number of patients and longer duration of follow-up are required to substantiate these observations. |
| اللغة: | English |
| تدمد: | 2230-9500 2230-8210 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be559772e6b07a8c9e9603e669d26a86Test http://europepmc.org/articles/PMC4192991Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....be559772e6b07a8c9e9603e669d26a86 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22309500 22308210 |
|---|